Neurology. 2025 Apr 8;104(7_Supplement_1):4223. doi: 10.1212/WNL.0000000000211531. Epub 2025 Apr 7.
ABSTRACT
OBJECTIVE: This study aims to analyze the rates of discontinuation and nonpublication in clinical trials related to gliomas, highlighting factors that contribute to these issues.
BACKGROUND: Gliomas are complex tumors that present significant challenges in research and treatment. Despite numerous clinical trials, a substantial number are discontinued or unpublished, impacting the overall knowledge base and treatment strategies for glioma patients.
DESIGN/METHODS: We conducted a comprehensive analysis using data extracted from the ClinicalTrials.gov database. A total of 1,441 trials were identified and categorized based on their completion and publication status. We examined various trial characteristics, including participant demographics, enrollment size, study design, and funding sources. Statistical regression models were employed to identify predictors of trial discontinuation and nonpublication.
RESULTS: Among the identified trials, 1,092 (75.8%) were completed, while 349 (24.2%) were discontinued. Of the completed trials, 641 (44.5%) were published. Larger enrollment sizes and multi-center designs significantly reduced the likelihood of discontinuation (Odds Ratio [OR] = 0.215; p < 0.001) and nonpublication (OR = 0.481; p < 0.001).
CONCLUSIONS: The high rates of discontinuation and nonpublication in glioma trials underscore the need for improved research methodologies. Focusing on larger, multi-center collaborations could enhance trial completion and publication rates, ultimately benefiting glioma research and patient outcomes. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Arafeh has nothing to disclose. Dr. Zakria has nothing to disclose. Ms. G Hamam has nothing to disclose. Dr. Hassan has nothing to disclose. Dr. Alajarmeh has nothing to disclose. Dr. Abed has nothing to disclose. Mr. Alsalhen has nothing to disclose.
PMID:40194228 | DOI:10.1212/WNL.0000000000211531
